Genus plc (GENSF)
USD 25.1
(0.0%)
USD 25.1
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | 7.9 Million USD | -76.28% |
| 2023 | 33.3 Million USD | -18.58% |
| 2022 | 40.9 Million USD | -37.41% |
| 2021 | 65.34 Million USD | 85.11% |
| 2020 | 35.3 Million USD | 352.56% |
| 2019 | 7.8 Million USD | -81.73% |
| 2018 | 42.7 Million GBP | 30.18% |
| 2017 | 32.8 Million GBP | -50.23% |
| 2016 | 65.9 Million GBP | 65.17% |
| 2015 | 39.9 Million GBP | 38.06% |
| 2014 | 28.9 Million GBP | 23.5% |
| 2013 | 23.4 Million GBP | -40.76% |
| 2012 | 39.5 Million GBP | 35.27% |
| 2011 | 29.2 Million GBP | 6.18% |
| 2010 | 27.5 Million GBP | 53.63% |
| 2009 | 17.9 Million GBP | 1.13% |
| 2008 | 17.7 Million GBP | 21.23% |
| 2007 | 14.6 Million GBP | 0.0% |
| 2006 | - GBP | -100.0% |
| 2005 | 5.9 Million GBP | 11.95% |
| 2004 | 5.27 Million GBP | 91.47% |
| 2003 | 2.75 Million GBP | 387.43% |
| 2002 | 565 Thousand GBP | -62.28% |
| 2001 | 1.49 Million GBP | -56.35% |
| 2000 | 3.43 Million GBP | -13.05% |
| 1999 | 3.94 Million GBP | 24.94% |
| 1998 | 3.15 Million GBP | -30.53% |
| 1997 | 4.54 Million GBP | 952.55% |
| 1996 | 432 Thousand GBP | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 6.75 Million GBP | -73.28% |
| 2024 Q2 | 17.18 Million USD | 154.6% |
| 2024 FY | 9.98 Million USD | -70.01% |
| 2024 Q4 | -7.08 Million USD | 0.0% |
| 2023 Q2 | 16.2 Million USD | 141.88% |
| 2023 Q1 | 6.7 Million GBP | -36.19% |
| 2023 Q3 | 9.95 Million GBP | -38.6% |
| 2023 Q4 | 25.25 Million USD | 153.86% |
| 2023 FY | 33.3 Million USD | -18.58% |
| 2022 Q1 | 9.95 Million GBP | 16.37% |
| 2022 FY | 40.9 Million USD | -37.41% |
| 2022 Q3 | 10.5 Million GBP | 5.53% |
| 2022 Q2 | 9.95 Million USD | 0.0% |
| 2022 Q4 | 10.5 Million USD | 0.0% |
| 2021 FY | 65.34 Million USD | 85.11% |
| 2021 Q2 | 15.1 Million USD | 0.0% |
| 2021 Q1 | 15.1 Million GBP | 160.34% |
| 2021 Q4 | 8.55 Million USD | 0.0% |
| 2021 Q3 | 8.55 Million GBP | -43.38% |
| 2020 Q2 | 11.85 Million USD | 0.0% |
| 2020 Q4 | 5.8 Million USD | 0.0% |
| 2020 FY | 35.3 Million USD | 352.56% |
| 2020 Q1 | 11.85 Million GBP | 58.0% |
| 2020 Q3 | 5.8 Million GBP | -51.05% |
| 2019 Q1 | -3.6 Million GBP | -1300.0% |
| 2019 Q3 | 7.5 Million GBP | 308.33% |
| 2019 FY | 7.8 Million USD | -81.73% |
| 2019 Q4 | 7.5 Million USD | 0.0% |
| 2019 Q2 | -3.6 Million GBP | 0.0% |
| 2018 Q1 | 21.05 Million GBP | 70.45% |
| 2018 Q2 | 21.05 Million GBP | 0.0% |
| 2018 FY | 42.7 Million GBP | 30.18% |
| 2018 Q3 | 300 Thousand GBP | -98.57% |
| 2018 Q4 | 300 Thousand GBP | 0.0% |
| 2017 Q4 | 12.35 Million GBP | 0.0% |
| 2017 FY | 32.8 Million GBP | -50.23% |
| 2017 Q1 | 4.05 Million GBP | -79.07% |
| 2017 Q2 | 4.05 Million GBP | 0.0% |
| 2017 Q3 | 12.35 Million GBP | 204.94% |
| 2016 FY | 65.9 Million GBP | 65.17% |
| 2016 Q4 | 19.35 Million GBP | 0.0% |
| 2016 Q3 | 19.35 Million GBP | 265.09% |
| 2016 Q2 | 5.3 Million GBP | 0.0% |
| 2016 Q1 | 5.3 Million GBP | -46.73% |
| 2015 FY | 39.9 Million GBP | 38.06% |
| 2015 Q3 | 9.95 Million GBP | -0.5% |
| 2015 Q1 | 10 Million GBP | 70.94% |
| 2015 Q2 | 10 Million GBP | 0.0% |
| 2015 Q4 | 9.95 Million GBP | 0.0% |
| 2014 Q4 | 5.85 Million GBP | 0.0% |
| 2014 FY | 28.9 Million GBP | 23.5% |
| 2014 Q3 | 5.85 Million GBP | -31.98% |
| 2014 Q2 | 8.6 Million GBP | 0.0% |
| 2014 Q1 | 8.6 Million GBP | 115.0% |
| 2013 Q2 | - GBP | 0.0% |
| 2013 FY | 23.4 Million GBP | -40.76% |
| 2013 Q4 | 4 Million GBP | 0.0% |
| 2013 Q3 | 4 Million GBP | 0.0% |
| 2012 Q2 | - GBP | 0.0% |
| 2012 FY | 39.5 Million GBP | 35.27% |
| 2011 FY | 29.2 Million GBP | 6.18% |
| 2011 Q2 | - GBP | 0.0% |
| 2010 FY | 27.5 Million GBP | 53.63% |
| 2010 Q2 | - GBP | 0.0% |
| 2009 FY | 17.9 Million GBP | 1.13% |
| 2009 Q2 | - GBP | 0.0% |
| 2008 Q2 | - GBP | 0.0% |
| 2008 FY | 17.7 Million GBP | 21.23% |
| 2007 Q2 | - GBP | 0.0% |
| 2007 FY | 14.6 Million GBP | 0.0% |
| 2006 FY | - GBP | -100.0% |
| 2006 Q1 | - GBP | 0.0% |
| 2005 FY | 5.9 Million GBP | 11.95% |
| 2005 Q1 | - GBP | 0.0% |
| 2004 Q1 | - GBP | 0.0% |
| 2004 FY | 5.27 Million GBP | 91.47% |
| 2003 FY | 2.75 Million GBP | 387.43% |
| 2002 FY | 565 Thousand GBP | -62.28% |
| 2001 FY | 1.49 Million GBP | -56.35% |
| 2000 FY | 3.43 Million GBP | -13.05% |
| 1999 FY | 3.94 Million GBP | 24.94% |
| 1998 FY | 3.15 Million GBP | -30.53% |
| 1997 FY | 4.54 Million GBP | 952.55% |
| 1996 FY | 432 Thousand GBP | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 691.569% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 213.135% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 85.088% |
| Nascent Biotech, Inc. | -2.08 Million USD | 478.41% |
| Rebus Holdings, Inc. | -1.02 Million USD | 874.51% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 87.871% |
| Qrons Inc. | -789.34 Thousand USD | 1100.827% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 1349.196% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 112.62% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 2001.42% |
| Skye Bioscience, Inc. | -37.64 Million USD | 120.986% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 110.539% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 220.132% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 2989.518% |
| SQZ Biotechnologies Company | -79.46 Million USD | 109.942% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 373.13% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 533.94% |
| Mesoblast Limited | -87.95 Million USD | 108.982% |
| Marizyme, Inc. | -65.34 Million USD | 112.089% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 172.532% |
| Pharming Group N.V. | -10.54 Million USD | 174.896% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 464.087% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 312.925% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 189.326% |
| ContraFect Corporation | -65.15 Million USD | 112.125% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 261.684% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 557.32% |
| IMV Inc. | -36.48 Million USD | 121.652% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 198.019% |
| MultiCell Technologies, Inc. | -380.07 USD | 2078664.475% |
| ONE Bio Corp. | 8.67 Million USD | 8.951% |
| Accustem Sciences Inc. | -3.74 Million USD | 310.868% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 115.283% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 723.454% |
| Q BioMed Inc. | -2.05 Million USD | 484.973% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 311.626% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 431.811% |
| Biomind Labs Inc. | -1.21 Million USD | 750.57% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 113.227% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 354.693% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 199.961% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 505.284% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | 52851.068% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 149.775% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 235.803% |
| GB Sciences, Inc. | -1.36 Million USD | 680.167% |
| Alpha Cognition Inc. | -13.77 Million USD | 157.36% |
| HST Global, Inc. | -146.21 Thousand USD | 5503.187% |
| CSL Limited | 2.64 Billion USD | 99.701% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 550.201% |
| Halberd Corporation | -79.67 Thousand USD | 10015.156% |
| Enzolytics Inc. | -2.17 Million USD | 462.913% |
| Agentix Corp. | -1.37 Million USD | 674.875% |
| Resverlogix Corp. | -3.61 Million USD | 318.837% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 349.099% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -295.05 Million USD | 102.677% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | -7961.224% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | -14.086% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 298.843% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 361.059% |
| AVAX Technologies, Inc. | -6.41 Million USD | 223.175% |
| Zenith Capital Corp. | -10.59 Million USD | 174.556% |
| Genscript Biotech Corporation | -95.47 Million USD | 108.274% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | 34090.19% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 290.548% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 13170.682% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 493.992% |
| Kadimastem Ltd | -3.3 Million USD | 338.858% |
| Helix BioMedix, Inc. | -1.05 Million USD | 848.066% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 306.86% |
| BioStem Technologies, Inc. | -8.48 Million USD | 193.128% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 1889.886% |
| LadRx Corporation | 400.44 Thousand USD | -1872.815% |
| Cell Source, Inc. | -5.32 Million USD | 248.462% |
| Regen BioPharma, Inc. | 1.02 Million USD | -671.855% |
| Regen BioPharma, Inc. | 1.02 Million USD | -671.855% |
| NovAccess Global Inc. | -4.76 Million USD | 265.647% |
| Affymax, Inc. | -14.42 Million USD | 154.77% |
| Itoco Inc. | -1.86 Million USD | 522.687% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 277.826% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 573.337% |
| Mobile Lads Corp. | -2.26 Million USD | 449.049% |
| CytoDyn Inc. | -49.84 Million USD | 115.85% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 10095.825% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 3562.983% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 939.061% |
| SYBLEU INC | -180.3 Thousand USD | 4481.489% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 589.85% |
| International Stem Cell Corporation | -131 Thousand USD | 6130.534% |
| Bioxytran, Inc. | -4.28 Million USD | 284.579% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | 14656.309% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 412.222% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 116.434% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 473.699% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 1111.67% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 349.369% |
| Neutra Corp. | -233.46 Thousand USD | 3483.805% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 138.934% |
| PureTech Health plc | -65.69 Million USD | 112.025% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 137.148% |
| IXICO plc | -1.17 Million USD | 770.628% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 179.581% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 113.829% |
| CSL Limited | 2.64 Billion USD | 99.701% |
| Cellectis S.A. | -103.17 Million USD | 107.657% |